基因智能控股
WGS
63.61
-6.61
-9.41%
基因智能控股
US · WGS
#2702 按市值排名
上市于 1970
63.61
-6.61
-9.41%
实时 - 追踪5344个代码 - 心跳于419秒前
· 2026-10-16 20:02
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了3家。
- 机构持股总比例下降了2.7个百分点。
机构持股
- 机构持股比例
- 106.04% -2.65pp
- 机构数量
- 279 -3
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund48.19%
Hedge Fund26.34%
VC/PE Fund14.91%
Public Company11.56%
Private Company3.17%
Individual/Insider1.86%
Sovereign Wealth Fund0.92%
Government Pension Fund0.71%
Insurance Company0.16%
主要股东 截至 2026-06-30
Corvex Management LP
16.04% · 4.78M 股
Casdin Capital, LLC
12.43% · 3.71M 股
BlackRock
5.72% · 1.71M 股
The Goldman Sachs Group, Inc.
5.48% · 1.63M 股
ARK Investment Management LLC
5.30% · 1.58M 股
William Blair Investment Management, LLC
4.78% · 1.42M 股
Vanguard Capital Management, LLC
3.46% · 1.03M 股
Morgan Stanley
3.29% · 980.52K 股
Citadel Advisors LLC
2.90% · 865.46K 股
First Light Asset Management, LLC
2.63% · 783.92K 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 34次买入 · 16次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Corvex Management LP | -- | 16.04% |
| Casdin Capital, LLC | -- | 12.43% |
| Joshua Ruch | Independent Director | 0.52% |
| Jason Ryan | Executive Chair of the Board | 0.40% |
| Katherine Stueland | Chief Executive Officer | 0.39% |
| Richard Pfenniger | Director | 0.15% |
| Kevin Feeley | Senior VP of Operations & CFO | 0.15% |
| Emily Leproust | Independent Director | 0.08% |
| Eli Casdin | Independent Director | 0.08% |
| Keith Meister | Independent Director | 0.08% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-16 | Thomas Fuchs | Director | Derivative Exercise and Retained | +1,146 | -- |
| 2026-09-15 | Katherine Stueland | Chief Executive Officer | Derivative Exercise and Sale | -10,501 | $94.26–99.00 |
| 2026-09-15 | Katherine Stueland | Chief Executive Officer | Derivative Exercise and Retained | +8,249 | -- |
| 2026-09-15 | Kevin Feeley | Senior VP of Operations & CFO | Derivative Exercise and Sale | -3,728 | $94.26–99.00 |
| 2026-09-15 | Kevin Feeley | Senior VP of Operations & CFO | Derivative Exercise and Retained | +3,469 | -- |
| 2026-09-08 | Katherine Stueland | Chief Executive Officer | Derivative Exercise and Sale | -3,692 | $84.22 |
| 2026-09-08 | Katherine Stueland | Chief Executive Officer | Derivative Exercise and Retained | +2,855 | -- |
| 2026-09-08 | Kevin Feeley | Senior VP of Operations & CFO | Derivative Exercise and Sale | -1,285 | $84.22 |
| 2026-09-08 | Kevin Feeley | Senior VP of Operations & CFO | Derivative Exercise and Retained | +1,177 | -- |
| 2026-08-31 | Kevin Feeley | Senior VP of Operations & CFO | Derivative Exercise and Sale | -372 | $83.84 |
| 2026-08-31 | Kevin Feeley | Senior VP of Operations & CFO | Derivative Exercise and Retained | +345 | -- |
| 2026-06-28 | Mark Gardner | President | Other Derivative Acquisition | +35,441 | -- |
| 2026-06-17 | Rho Capital Partners, Inc. | -- | Other Derivative Acquisition | +4,248 | -- |
| 2026-06-17 | Rho Capital Partners, Inc. | -- | Derivative Exercise and Retained | +3,576 | -- |
| 2026-06-17 | Richard Pfenniger | Director | Other Derivative Acquisition | +4,248 | -- |
| 2026-06-17 | Richard Pfenniger | Director | Derivative Exercise and Retained | +3,576 | -- |
| 2026-06-17 | Keith Meister | Independent Director | Other Derivative Acquisition | +4,248 | -- |
| 2026-06-17 | Keith Meister | Independent Director | Derivative Exercise and Retained | +3,576 | -- |
| 2026-06-17 | Eli Casdin | Independent Director | Other Derivative Acquisition | +4,248 | -- |
| 2026-06-17 | Eli Casdin | Independent Director | Derivative Exercise and Retained | +3,576 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:02:21 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
基因智能控股 讨论区 0 条评论